

Antiretroviral Drug Interactions

Charts revised October 2009. Full information available at www.hiv-druginteractions.org

	PROTEASE INHIBITORS								NNRTIs				NRTIs						OTHER			
	ATV	DRV	FPV	IDV	LPV	NFV	RTV	SQV	TPV	DLV	EFV	ETR	NVP	ABC	ddl	FTC	3TC	d4T	TDF	ZDV	MVC	RAL
PIs																						
Atazanavir	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Darunavir	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Fosamprenavir	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Indinavir	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Lopinavir	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Nelfinavir	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Ritonavir	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Saquinavir	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Tipranavir	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
NNRTIs																						
Delavirdine	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Efavirenz	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Etravirine	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Nevirapine	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
NRTIs																						
Abacavir	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Didanosine (ddl)	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Emtricitabine (FTC)	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Lamivudine (3TC)	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Stavudine (d4T)	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Tenofovir	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Zidovudine (AZT/ZDV)	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Other																						
Elvitegravir	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	n/a
Enfuvirtide (T20)	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Maraviroc	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊
Raltegravir	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊	◊

Key to abbreviations

ATV	Atazanavir (Reyataz®)
DRV	Darunavir (Prezista®)
FPV	Fosamprenavir (Telzir®, Lexiva®)
IDV	Indinavir (Crixivan®)
LPV	Lopinavir (Kaletra®)
NFV	Nelfinavir (Viracept®)
RTV	Ritonavir (Norvir®)
SQV	Saquinavir (Invirase®)
TPV	Tipranavir (Aptivus®)

DLV	Delavirdine (Rescriptor®)
EFV	Efavirenz (Sustiva®, Stocrin®)
ETR	Etravirine (Intelence®)
NVP	Nevirapine (Viramune®)
ABC	Abacavir (Ziagen®)
ddl	Didanosine (Videx®, Videx-EC®)
FTC	Emtricitabine (Emtriva®)
3TC	Lamivudine (Epivir®)
d4T	Stavudine (Zerit®)
TDF	Tenofovir (Viread®)
ZDV	Zidovudine (Retrovir®)

NRTI Coformulations

Combivir® (Lamivudine + Zidovudine)	
Kivexa® (Abacavir + Lamivudine)	Trizivir® (Abacavir + Lamivudine + Zidovudine)
Truvada® (Emtricitabine + Tenofovir)	Atripla® (Emtricitabine + Tenofovir + Efavirenz)

Key to symbols

Filled symbols indicate further information on the interaction is available at www.hiv-druginteractions.org.

Empty symbols indicate the combination has not been studied; an interaction has been predicted based on the metabolic profiles of the drugs.

●/○	These drugs should not be coadministered
◻/◻	Potential interaction – may require close monitoring, alteration of drug dosage or timing of administration
◊/◊	No clinically significant interaction expected
n/a	Not applicable. Unlikely to be coadministered.

Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option.

© Liverpool HIV Pharmacology Group, University of Liverpool
Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place,
LIVERPOOL, L69 3GF

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.